Audited Financial results for Year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr Lalchandani Labs reported total revenue of Rs. 446.13 lacs for FY25, down from Rs. 504.50 lacs in FY24, a decline of about 11.5%. Net profit stood at approximately Rs. 36.53 lacs versus Rs. 51.79 lacs last year. The company booked an exceptional gain of Rs. 119.01 lacs, including a Rs. 12.13 lac one-time settlement (OTS) gain from settling unsecured loans with banks and NBFCs. Cash and cash equivalents improved to Rs. 329.73 lacs from Rs. 229.24 lacs. Short-term borrowings rose to Rs. 406.71 lacs from Rs. 321.56 lacs. The auditor issued a qualified opinion, noting the company's loan accounts are classified as NPAs, no working capital limits were sanctioned, statutory dues like PF, ESIC and TDS remain unpaid, and gratuity/leave encashment liabilities were not provisioned. The auditor also included an emphasis of matter on unconfirmed balances and absence of doubtful debt provisions.
Multiple red flags — NPA status with lenders, unpaid statutory dues, missing employee benefit provisions, and a qualified audit opinion — raise serious concerns about the company's financial health and governance despite a positive bottom line. Shareholders should view this with caution as the profitability is partially supported by one-time OTS gains rather than core operations.